Computational Pathology Market: as Roche's pending acquisition of PathAI for up to USD 1.05 Billion confirms that AI-powered pathology analysis has moved from research curiosity to required infrastructure for any diagnostics company that wants to remain competitive in companion diagnostic development, the FDA's Predetermined Change Control Plan framework removes the regulatory friction that previously blocked continuous algorithm improvement, so per-clearance revenue compounds above the traditional one-clearance-one-algorithm model, and the pharmaceutical drug development tool application category creates a monetisation pathway for computational pathology vendors that does not depend on hospital laboratory digitisation completing first.

The global computational pathology market size was USD 1.35 Billion in 2025 and is expected to register a revenue CAGR of 19.6% during the forecast period. Market revenue growth is driven by factors such as Roche's pending acquisition of PathAI for up to USD 1.05 Billion confirming that major in vitro diagnostics companies view AI-powered pathology as required infrastructure, the FDA's maturation of the Predetermined Change Control Plan framework enabling continuous algorithm improvement without new regulatory submissions, and the pharmaceutical drug development tool application category creating a monetisation pathway independent of hospital laboratory digitisation progress. The first driving factor is institutional validation of AI pathology as required diagnostics infrastructure by Roche's pending up-to-USD-1.05-Billion PathAI acquisition. The deal signals that in vitro diagnostics companies lacking AI pathology strategies face being locked out of the premium companion diagnostic market segment where AI algorithms that can serve as companion diagnostics command premium pricing and durable competitive advantages. The second driving factor is the FDA's Predetermined Change Control Plan framework maturation, with 56 PCCPs authorised since July 2023 enabling specific future algorithm enhancements without new regulatory submissions for each update, addressing the single largest regulatory friction point that had previously blocked continuous AI model improvement. The third driving factor is the pharmaceutical drug development tool application category for clinical trial endpoint assessment, which provides a near-term revenue pathway for computational pathology vendors at pharmaceutical company sponsors who can realise immediate quantifiable return on investment from AI-assisted histological scoring without waiting for hospital pathology laboratory digitisation to complete. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each FDA-cleared computational pathology AI algorithm generates a deployed model that can be enhanced through the PCCP framework without requiring a new regulatory submission, which compounds algorithm improvement speed and per-clearance revenue above what the traditional one-clearance-one-static-algorithm regulatory model could support. Once a computational pathology platform has an FDA 510(k) clearance with a Predetermined Change Control Plan attached, each pre-authorised algorithm enhancement the company delivers generates incremental platform capability without resetting the regulatory clock, so the per-clearance investment compounds in value as the underlying AI model quality improves continuously around the same cleared platform. As a result, demand and revenue share are concentrating around the computational pathology platforms with the deepest FDA regulatory track record and the broadest PCCP pre-authorised enhancement scope, and the forecast tilts toward PathAI and Paige whose clearance histories include PCCP-enabled continuous improvement rather than static-algorithm competitors who must re-file for each substantive model update. For instance, in June 2025, PathAI received FDA 510(k) clearance for its evolved AISight Dx digital pathology platform for primary diagnosis, specifically including a Predetermined Change Control Plan enabling specific future enhancements without new regulatory submissions, building on the company's initial 2022 AISight Dx clearance and confirming the PCCP framework as the commercial enabler of the continuous improvement model that distinguishes leading platforms from conventional regulated medical device competitors. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the Roche-PathAI definitive merger agreement announced in May 2026, which values PathAI at USD 750 Million in upfront cash plus up to USD 300 Million in contingent milestone payments and signals to the entire in vitro diagnostics industry that AI-powered pathology analysis has crossed from research-stage differentiation to required commercial infrastructure. The acquisition signals work as a demand driver because in vitro diagnostics companies observing Roche choose to own a computational pathology platform outright rather than rely on external partnerships will independently conclude that their own competitive position in companion diagnostic development requires equivalent AI pathology capability, accelerating the industry-wide adoption of AI pathology platforms that would otherwise follow a slower customer-by-customer evaluation cycle. Roche entered the definitive merger agreement to acquire PathAI, headquartered in Boston, Massachusetts, for USD 750 Million in upfront cash with additional contingent payments of up to USD 300 Million, adding PathAI's AISight digital pathology platform and AI-based biomarker algorithms to Roche's diagnostics division which generated approximately CHF 10.30 Billion in revenue in 2024. PathAI received FDA 510(k) clearance and a CE Mark for AISight Dx, enabling use for primary diagnosis in clinical settings, while the company separately announced a strategic partnership with Quest Diagnostics in 2024 including the sale of PathAI Diagnostics and licensing of AISight to one of the largest reference laboratory networks in the United States, confirming the platform's deployment readiness at commercial scale before the Roche acquisition announcement. The effect on the market is an accelerated industry-wide investment cycle in AI pathology platforms as diagnostics companies across the market conclude that AI pathology capability is a minimum competitive requirement for participation in the companion diagnostic development ecosystem. These are some of the key factors driving revenue growth of the market.

The second driver is the maturation of the FDA's regulatory framework for AI-powered pathology software as a medical device, specifically the Predetermined Change Control Plan mechanism that allows computational pathology developers to deliver pre-authorised algorithm enhancements without requiring new FDA submissions for each incremental model improvement. Regulatory framework maturation works as a demand driver because investors and hospital procurement committees previously treated AI pathology platforms with regulatory uncertainty as a commercial risk that justified delaying procurement decisions, and the PCCP framework's operationalisation demonstrates that AI pathology tools can maintain regulatory standing while continuously improving, removing one of the structural risk factors that had suppressed commercial adoption. In April 2025, Paige received FDA Breakthrough Device designation for PanCancer Detect, described as the first AI tool designed to identify both common and rare cancer variants across multiple tissue types, extending the company's regulatory track record following its landmark 2021 FDA de novo marketing authorisation for Paige Prostate. In June 2025, PathAI received FDA 510(k) clearance for its evolved AISight Dx digital pathology platform for primary diagnosis, specifically including a Predetermined Change Control Plan, building on its initial 2022 clearance, and Modella AI's PathChat DX generative AI co-pilot for diagnostic workflows earned FDA Breakthrough Device designation in January 2025. The FDA's publicly available database of 510(k) marketing clearances included 56 entries incorporating Predetermined Change Control Plans as of mid-2025, all authorised since July 2023, indicating the regulatory framework has matured substantially since its initial introduction. The effect on the market is a structural reduction in the regulatory uncertainty discount that was previously embedded in computational pathology platform valuations, enabling more aggressive commercial pricing and faster laboratory procurement decisions as the regulatory risk premium compresses. These are some of the key factors driving revenue growth of the market.

"The 56 Predetermined Change Control Plans authorised since July 2023 is the number that tells you the FDA has genuinely operationalised this pathway rather than just announcing it. Without the PCCP framework, every meaningful algorithm improvement required a new FDA submission, which is exactly the friction that kills software businesses built on continuous model improvement. Roche paying up to USD 1.05 Billion for a company whose revenues at most accounts do not yet match that valuation only makes sense if you believe AI pathology becomes the default interpretation layer for essentially all tissue-based diagnostics within the next five to seven years."

Clarivant Analyst Intelligence, Q1 2026

The third driver is the pharmaceutical drug development tool application category, where AI-assisted histological endpoint assessment in clinical trials provides computational pathology vendors with a direct revenue pathway at pharmaceutical company sponsors who can realise immediate, quantifiable return on investment from AI scoring standardisation without requiring any hospital pathology laboratory to complete its digital transformation first. Drug development tool applications work as a demand driver because pharmaceutical companies running clinical trials face acute pain from inter-rater variability in histological endpoint assessment and the time cost of manual pathological scoring at scale, problems that AI tools can demonstrably and immediately address, so the commercial case for DDT procurement does not depend on the gradual adoption curve that constrains hospital pathology laboratory AI software revenue. PathAI received EMA and FDA qualification of its AIM-MASH AI Assist tool as the first AI-powered pathology Drug Development Tool for metabolic dysfunction-associated steatohepatitis clinical trials, providing a validated AI-based endpoint assessment tool for the growing MASH drug development pipeline and confirming the regulatory pathway for DDT qualification across pharma-relevant disease areas. The effect on the market is a separate and earlier-monetising revenue stream for computational pathology vendors that does not compete with hospital laboratory digitisation timelines and grows with the pharmaceutical drug development pipeline rather than with hospital capital budget cycles. These are some of the key factors driving revenue growth of the market.

However, the computational pathology market faces adoption constraints from the slow pace of pathology laboratory transition from conventional microscope-based slide examination to digital whole-slide imaging infrastructure, which creates a structural deployment ceiling that limits where commercial AI pathology algorithms can actually generate clinical revenue regardless of their regulatory clearance status. The transition pace constraint is structural rather than simply technological because the decision to invest in whole-slide imaging scanner infrastructure at a hospital pathology laboratory involves multi-year capital budget cycles, institutional change management for pathologist workflow adoption, and information technology integration projects that cannot be compressed by superior AI algorithm performance or even competitive scanner pricing, so the addressable deployment base for AI pathology tools expands at the pace of institutional capital budget cycles rather than at the pace of AI algorithm development. Whole-slide imaging capital cost compounds this, since Philips IntelliSite, Leica Aperio, and Hamamatsu NanoZoomer scanner platforms carry upfront hardware investment costs that smaller community hospital pathology departments and independent pathology laboratories cannot justify against their annual case volumes, concentrating the early commercial AI pathology deployment base at large academic medical centres and national reference laboratory networks that represent a meaningful but bounded fraction of the total global pathology laboratory base. Evolving AI and machine learning SaMD regulatory guidance is a third constraint, since even with 56 PCCPs authorised since July 2023, computational pathology developers must navigate guidance that continues to evolve across FDA, EMA, and national regulatory bodies simultaneously, creating validation study design uncertainty that disproportionately burdens smaller developers who cannot spread the regulatory development cost across large existing product portfolios as Roche and Philips can. These factors substantially limit computational pathology market growth over the forecast period.

Based on product, the global computational pathology market is segmented into AI image analysis software, whole-slide imaging scanners, and image management and storage platforms. AI image analysis software holds the largest revenue share, because the core algorithmic capability distinguishes computational pathology platforms from conventional whole-slide imaging digitisation infrastructure that simply converts glass slides into viewable digital images without diagnostic interpretation assistance, and the software licence and subscription revenue model generates recurring revenue from the same laboratory infrastructure without requiring replacement capital purchases at each contract renewal. PathAI's AISight, Paige's FullFocus and PanCancer Detect, and Roche's VENTANA digital pathology algorithms represent three of the largest commercial computational pathology software platforms deployed globally, with PathAI having leveraged data from more than 32.5 million annotations provided by its network of more than 450 pathologists to train its AI models. Image management and storage platforms is expected to register a rapid revenue growth rate in the global computational pathology market over the forecast period, driven by expanding whole-slide image data volume as digital pathology adoption accelerates and laboratories require centralised infrastructure to manage, archive, and retrieve increasingly large digital slide libraries that cannot be practically managed in conventional file storage systems.

Based on application, the global computational pathology market is segmented into cancer diagnosis and grading, companion diagnostic biomarker scoring, drug development tools, and primary diagnosis workflow. Cancer diagnosis and grading holds the largest revenue share, reflecting the established commercial track record of Paige Prostate as the first FDA-cleared AI-based pathology product and the growing deployment of cancer detection and grading algorithms at hospital pathology laboratory oncology diagnostic workflows. Companion diagnostic biomarker scoring is expected to register a rapid revenue growth rate in the global computational pathology market over the forecast period, driven by Roche's acquisition of PathAI to strengthen AI-assisted companion diagnostic IHC biomarker scoring and Agilent Technologies's collaboration with PathAI to extend AI interpretation into Dako's companion diagnostic IHC platform, with pharmaceutical companies increasingly requiring quantitative AI-assisted biomarker scoring to support companion diagnostic regulatory submissions across PD-L1 and other tumour biomarker assays.

Based on technology, the global computational pathology market is segmented into deep learning and foundation models, image segmentation algorithms, and Predetermined Change Control Plans. Deep learning and foundation models hold the largest revenue share, because the supervised deep learning approach trained on large annotated pathology image libraries has delivered the validated clinical performance levels needed to achieve FDA clearance across cancer detection and grading applications, and the foundation model paradigm enables training on unlabelled slide data at scale that dramatically reduces the annotation burden previously limiting AI model development to well-resourced organisations. Image segmentation algorithms remain the underlying computational engine for tumour boundary delineation and tissue compartment identification tasks that are prerequisites for quantitative biomarker scoring applications. Predetermined Change Control Plan-enabled algorithm improvement is expected to register a rapid revenue growth rate in the global computational pathology market over the forecast period, driven by the 56 PCCPs authorised since July 2023 that enable the leading cleared platforms to deliver continuous model improvement to their installed base, with PathAI and Paige positioned as first movers in the PCCP-enabled continuous improvement model.

Based on regional analysis, the computational pathology market in North America accounted for largest revenue share in 2025. The United States leads because PathAI and Paige are both headquartered in the United States, the FDA has the most mature and operationally active regulatory pathway for AI pathology software as a medical device including the 56 authorised PCCPs, and the largest US academic medical centres and national reference laboratory networks including Quest Diagnostics represent the most commercially advanced digital pathology infrastructure deployment base. The PathAI-Quest Diagnostics strategic partnership announced in 2024 including the sale of PathAI Diagnostics and AISight platform licensing confirms that the largest US reference laboratory network is already deploying commercial AI pathology infrastructure, and the planned integration of PathAI into Roche's diagnostics division following the pending acquisition will further concentrate the leading AI pathology platform development resources in the North American market.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national computational pathology markets within Europe. The European computational pathology revenue opportunity is concentrated in pharmaceutical drug development tool applications, particularly for AI-assisted histological endpoint scoring in MASH, NASH, and oncology clinical trials where the concentration of major European pharmaceutical company drug development operations makes the return on investment case for AI DDT procurement immediately quantifiable. The European IVDR regulatory framework governs AI pathology software as an in vitro diagnostic and requires IVDR compliance for clinical deployment at European accreditation-required laboratories, creating a regulatory compliance barrier for US-cleared AI pathology platforms seeking European laboratory deployment. The result is steady rather than rapid growth, shaped more by pharmaceutical DDT demand than by hospital laboratory AI deployment, as hospital digitisation proceeds at a more modest pace than in North America.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national computational pathology markets within the region, driven by expanding digital pathology infrastructure investment and acute pathologist workforce shortages in China that make AI-assisted pathology tools a structural workforce productivity solution rather than an optional enhancement. Japan's national pathology laboratory network is among the most advanced in Asia Pacific for digital whole-slide imaging infrastructure adoption, making Japan the primary early-launch market for AI pathology platforms receiving FDA clearance before separate PMDA approval, and this early adoption leaves more room for AI pathology revenue growth in China and South Korea than in markets where pathology AI tools are already standard at the leading oncology centres.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national computational pathology markets within the region, with adoption concentrated at private hospital network pathology laboratories and pharmaceutical company clinical trial sites in Sao Paulo, Mexico City, and Bogota. The Iran-US sanctions and Strait of Hormuz freight disruption have maintained elevated import costs for specialty whole-slide imaging scanner components and AI pathology platform server hardware entering Brazilian and Mexican distribution networks through 2026, contributing to slower hardware deployment timelines beyond the primary private hospital oncology centre markets.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial computational pathology markets within the GCC, driven by government investment in King Faisal Specialist Hospital and Research Centre and similar national oncology centre digitisation programmes under Vision 2030 healthcare modernisation plans. South Africa is the most established market on the African continent for digital pathology infrastructure, with National Health Laboratory Service and private pathology group PathCare operating digital pathology pilot programmes, while the Gulf states are still building the pathology laboratory workforce capacity and whole-slide imaging infrastructure needed to deploy AI pathology tools at clinical scale.